# SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Product name : Hardtop XP Comp A

UFI : F6PN-GTHC-8W0Q-KF6D

Product code : 3140
Product description : Paint.
Product type : Liquid.

Other means of : Not available.

identification

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use in coatings - Industrial use
Use in coatings - Professional use

#### 1.3 Details of the supplier of the safety data sheet

Jotun A/S Jotun Paints (Europe) Ltd.

P.O.Box 2021 Stather Road

3202 Sandefjord Flixborough, Scunthorpe Norway North Lincolnshire

Tel: + 47 33 45 70 00 DN15 8RR Fax: +47 33 45 72 42 England

E-mail: SDSJotun@jotun.no

Tel: +44 17 24 40 00 00 Fax: +44 17 24 40 01 00

#### 1.4 Emergency telephone number

**National advisory body/Poison Centre** 

Telephone number : Contact NHS Direct; phone 0845 4647 or 111. Open 24/7.

**Supplier** 

**Telephone number**: +47 33 45 70 00 Jotun Norway (head office)

#### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

<u>Classification according to UK CLP/GHS</u>

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 Aquatic Chronic 3, H412

The product is classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 1/23

### **SECTION 2: Hazards identification**

**Hazard pictograms** 





Signal word : Warning.

**Hazard statements** : H226 - Flammable liquid and vapour.

H315 - Causes skin irritation.

H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation.

H412 - Harmful to aquatic life with long lasting effects.

**Precautionary statements** 

General : Not applicable.

**Prevention**: P280 - Wear protective gloves. Wear eye or face protection.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

sources. No smoking.

P273 - Avoid release to the environment.

P261 - Avoid breathing vapour.

Response : P362 + P364 - Take off contaminated clothing and wash it before reuse.

P302 + P352 - IF ON SKIN: Wash with plenty of water.

P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P313 - If eye irritation persists: Get medical advice or attention.

Storage : Not applicable.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional,

national and international regulations.

Supplemental label

elements

EUH211 - Warning! Hazardous respirable droplets may be formed when sprayed.

Do not breathe spray or mist.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and

articles

Special packaging requirements

Containers to be fitted with child-resistant

fastenings

: Not applicable.

: Not applicable.

Tactile warning of danger : Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

vPvB.

Other hazards which do not result in classification

: None known.

**SECTION 3: Composition/information on ingredients** 

3.2 Mixtures : Mixture

Date of issue/Date of revision: 28.03.2023Date of previous issue: No previous validationVersion: 12/23

## **SECTION 3: Composition/information on ingredients**

Product/ingredient name	Identifiers	%	Classification	Туре
xylene	REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7 Index: 601-022-00-9	≥10 - ≤15	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
n-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4	≤10	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
ethylbenzene	REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4	≤5	Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
titanium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7 Index: 022-006-00-2	≤5	Carc. 2, H351 (inhalation)	[1] [2] [*]
hydrocarbons, C9, aromatics	REACH #: 01-2119455851-35 EC: 265-199-0 CAS: 64742-95-6	≤4.1	Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411	[1]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 Index: 607-195-00-7	<1	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
n-butyl methacrylate	REACH #: 01-2119486394-28 EC: 202-615-1 CAS: 97-88-1 Index: 607-033-00-5	<1	Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H335	[1]
2-Propenoic acid, 2-methyl-, 2- (dimethylamino)ethyl ester, polymer with butyl 2-propenoate, compd. with polyethylene glycol hydrogen maleate C9-11-alkyl ethers	CAS: 1259547-09-5	<1	Skin Sens. 1, H317	[1]
decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl- 4-piperidinyl) ester, mixt. with 1-methyl 10- (1,2,2,6,6-pentamethyl- 4-piperidinyl) decanedioate	CAS: 1065336-91-5	≤0.3	Skin Sens. 1A, H317 Repr. 2, H361f Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1)	[1]
mesitylene	EC: 203-604-4 CAS: 108-67-8 Index: 601-025-00-5	≤0.3	Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 2, H411	[1] [2]
silica, amorphous, fumed, cryst free	REACH #: 01-2119379499-16	≤0.1	Not classified.	[2]

Date of issue/Date of revision: 28.03.2023Date of previous issue: No previous validationVersion: 13/23

## **SECTION 3: Composition/information on ingredients**

talc (non-asbestos form)	EC: 231-545-4 CAS: 112945-52-5 EC: 238-877-9 CAS: 14807-96-6	≤0.1	Not classified.	[2]
Oleic acid, compound	EC: 251-846-4 CAS: 34140-91-5	≤0.1	Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT RE 2, H373 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 2, H411	[1]
dioctyltin dilaurate	EC: 222-883-3 CAS: 3648-18-8	≤0.1	Repr. 1B, H360D STOT RE 1, H372 (immune system)	[1] [2]
Toluene	REACH #: 01-2119471310-51 EC: 203-625-9 CAS: 108-88-3 Index: 601-021-00-3	≤0.1	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Repr. 2, H361d STOT SE 3, H336 STOT RE 2, H373 Asp. Tox. 1, H304	[1] [2]
maleic anhydride	REACH #: 01-2119472428-31 EC: 203-571-6 CAS: 108-31-6 Index: 607-096-00-9	≤0.1	Acute Tox. 4, H302 Skin Corr. 1B, H314 Eye Dam. 1, H318 Resp. Sens. 1, H334 Skin Sens. 1, H317 STOT RE 1, H372 (respiratory system) (inhalation) EUH071	[1] [2]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

#### **Type**

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

#### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

**Eye contact** 

: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.

Inhalation

: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 4/23

### **SECTION 4: First aid measures**

Skin contact

Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

#### **Protection of first-aiders**

: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

#### 4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains n-butyl methacrylate, 2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester, polymer with butyl 2-propenoate, comps. with polyethylene glycol hydrogen maleate C9-11-alkyl ethers, decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate. May produce an allergic reaction.

#### **Over-exposure signs/symptoms**

**Eye contact**: Adverse symptoms may include the following:

pain or irritation watering

redness

Inhalation : No specific data.

**Skin contact**: Adverse symptoms may include the following:

irritation redness

**Ingestion**: No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed.

The exposed person may need to be kept under medical surveillance for 48 hours.

**Specific treatments** : No specific treatment.

See toxicological information (Section 11)

Date of issue/Date of revision: 28.03.2023Date of previous issue: No previous validationVersion: 15/23

## SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media

: Recommended: alcohol-resistant foam, CO2, powders, water spray.

**Unsuitable extinguishing** media

: Do not use water jet.

#### 5.2 Special hazards arising from the substance or mixture

**Hazards from the** substance or mixture

: Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

**Hazardous combustion** products

: Decomposition products may include the following materials: carbon dioxide

carbon monoxide nitrogen oxides metal oxide/oxides

#### 5.3 Advice for firefighters

**Special protective actions** for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.

**Special protective** equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

## 6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

#### 6.3 Methods and material for containment and cleaning up

**Small spill** 

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill

: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent

Date of issue/Date of revision 6/23 : 28.03.2023 Date of previous issue Version :1 : No previous validation

### **SECTION 6: Accidental release measures**

material may pose the same hazard as the spilt product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

# 6.4 Reference to other sections

: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

## **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

#### **Protective measures**

Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.

# Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### **Seveso Directive - Reporting thresholds**

## **Danger criteria**

	Notification and MAPP threshold	Safety report threshold
P5c	5000 tonne	50000 tonne

See Technical Data Sheet / packaging for further information.

#### 7.3 Specific end use(s)

Recommendations : Not available.
Industrial sector specific : Not available.
solutions

## **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

Occupational exposure limits

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 7/23

## SECTION 8: Exposure controls/personal protection

Product/ingredient name	Exposure limit values
xylene	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 441 mg/m³ 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 220 mg/m³ 8 hours.
	TWA: 50 ppm 8 hours.
n-butyl acetate	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	STEL: 966 mg/m³ 15 minutes.
	STEL: 200 ppm 15 minutes.
	TWA: 724 mg/m³ 8 hours.
	TWA: 150 ppm 8 hours.
ethylbenzene	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 552 mg/m³ 15 minutes.
	STEL: 125 ppm 15 minutes.
	TWA: 100 ppm 8 hours.
	TWA: 441 mg/m³ 8 hours.
titanium dioxide	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	TWA: 4 mg/m <sup>3</sup> 8 hours. Form: respirable
	TWA: 10 mg/m³ 8 hours. Form: total inhalable
2-methoxy-1-methylethyl acetate	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 548 mg/m³ 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 274 mg/m³ 8 hours.
	TWA: 50 ppm 8 hours.
mesitylene	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	TWA: 25 ppm 8 hours.
	TWA: 125 mg/m³ 8 hours.
silica, amorphous, fumed, crystfree	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	TWA: 2.4 mg/m³ 8 hours. Form: respirable dust
	TWA: 6 mg/m³ 8 hours. Form: inhalable dust
talc (non-asbestos form)	EH40/2005 WELs (United Kingdom (UK), 1/2020).
	TWA: 1 mg/m³ 8 hours. Form: respirable dust
dioctyltin dilaurate	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 0.2 mg/m³, (as Sn) 15 minutes.
	TWA: 0.1 mg/m³, (as Sn) 8 hours.
Toluene	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed
	through skin.
	STEL: 384 mg/m³ 15 minutes.
	TWA: 191 mg/m³ 8 hours.
	TWA: 50 ppm 8 hours.
	STEL: 100 ppm 15 minutes.
maleic anhydride	EH40/2005 WELs (United Kingdom (UK), 1/2020). Inhalation
	sensitiser.
	STEL: 3 mg/m³ 15 minutes. TWA: 1 mg/m³ 8 hours.

#### **Biological exposure indices**

No exposure indices known.

procedures

Recommended monitoring: Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

**DNELs/DMELs** 

Date of issue/Date of revision : 28.03.2023 Version: 1 8/23 Date of previous issue : No previous validation

## **SECTION 8: Exposure controls/personal protection**

Product/ingredient name	Type	Exposure	Value	Population	Effects
xylene	DNEL	Long term	65.3 mg/m <sup>3</sup>	General	Local
		Inhalation		population	
	DNEL	Short term	260 mg/m <sup>3</sup>	General	Local
	DNEL	Inhalation Short term	260 mg/m³	population General	Systemic
	DIVLL	Inhalation	200 mg/m	population	Oysternic
	DNEL	Long term	221 mg/m <sup>3</sup>	Workers	Local
		Inhalation			
	DNEL	Long term Oral	12.5 mg/	General	Systemic
	DNEL	Long term	kg bw/day 65.3 mg/m³	population General	Systemic
	DIVLE	Inhalation	oo.o mg/m	population	Cystolino
	DNEL	Long term Dermal	125 mg/kg	General	Systemic
		l <u>-</u> .	bw/day	population	
	DNEL	Long term Dermal	212 mg/kg	Workers	Systemic
	DNEL	Long term	bw/day 221 mg/m³	Workers	Systemic
	DIVLE	Inhalation	2211119/111	VVOIRCIS	Oysternic
	DNEL	Short term	442 mg/m <sup>3</sup>	Workers	Local
		Inhalation	_		
	DNEL	Short term Inhalation	442 mg/m <sup>3</sup>	Workers	Systemic
n-butyl acetate	DNEL	Short term	960 mg/m³	Workers	Systemic
in baryi acctars	DIVLL	Inhalation	ooo mg/m	VVOINGIO	Cyclonno
	DNEL	Short term	960 mg/m <sup>3</sup>	Workers	Local
	5.151	Inhalation	400 / 3		
	DNEL	Long term Inhalation	480 mg/m <sup>3</sup>	Workers	Systemic
	DNEL	Long term	480 mg/m³	Workers	Local
	5.122	Inhalation	.00g/	TT GINGIO	2004.
	DNEL	Short term	859.7 mg/	General	Systemic
		Inhalation	m³	population	
	DNEL	Short term	859.7 mg/	[Consumers] General	Local
	DIVLL	Inhalation	m <sup>3</sup>	population	Local
				[Consumers]	
	DNEL	Long term	102.34 mg/	General	Systemic
		Inhalation	m³	population [Consumers]	
	DNEL	Long term	102.34 mg/	General	Local
	5.122	Inhalation	m <sup>3</sup>	population	2004.
				[Consumers]	
	DNEL	Short term Oral	2 mg/kg	General	Systemic
	DNEL	Long term Oral	bw/day 2 mg/kg	population General	Systemic
	DIVLL	Long tom Oral	bw/day	population	Cystollio
	DNEL	Short term Dermal	6 mg/kg	General	Systemic
	D	01	bw/day	population	0
	DNEL	Short term Dermal	11 mg/kg bw/day	Workers	Systemic
	DNEL	Long term	35.7 mg/m <sup>3</sup>	General	Local
		Inhalation	32g/111	population	
	DNEL	Short term	300 mg/m <sup>3</sup>	General	Local
	ראובי	Inhalation	200 1 3	population	Cyatanaia
	DNEL	Short term Inhalation	300 mg/m <sup>3</sup>	General population	Systemic
	DNEL	Long term	300 mg/m <sup>3</sup>	Workers	Local
		Inhalation	· ·		
	DNEL	Short term	600 mg/m <sup>3</sup>	Workers	Local
	DNEL	Inhalation Short term	600 mg/m <sup>3</sup>	Workers	Systemic
	DINCL	Inhalation	600 mg/m <sup>3</sup>	AA OI VGI 2	Systemic
	DNEL	Long term Dermal	3.4 mg/kg	General	Systemic

Date of issue/Date of revision: 28.03.2023Date of previous issue: No previous validationVersion: 19/23

## **SECTION 8: Exposure controls/personal protection**

 <u> </u>	-				
	DNEL	Long term Dermal	bw/day 7 mg/kg	population Workers	Systemic
	DNEL	Long term Inhalation	bw/day 12 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	48 mg/m³	Workers	Systemic
ethylbenzene	DNEL	Long term Oral	1.6 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	15 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	77 mg/m³	Workers	Systemic
	DNEL	Long term Dermal	180 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	293 mg/m³	Workers	Local
	DMEL	Long term Inhalation	442 mg/m <sup>3</sup>	Workers	Local
hda	DMEL	Short term Inhalation	884 mg/m³	Workers	Systemic
hydrocarbons, C9, aromatics	DNEL	Long term Dermal	12.5 mg/ kg bw/day 151 mg/m³	Workers Workers	Systemic Systemic
	DNEL	Long term Inhalation Long term Dermal	7.5 mg/kg	General	Systemic
	DINCE	Long term Dermai	bw/day	population [Consumers]	Systemic
	DNEL	Long term Inhalation	32 mg/m³	General population	Systemic
	DNEL	Long term Oral	7.5 mg/kg bw/day	[Consumers] General population [Consumers]	Systemic
2-methoxy-1-methylethyl acetate	DNEL	Long term Dermal	153.5 mg/ kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	275 mg/m³	Workers	Systemic
	DNEL	Long term Dermal	54.8 mg/ kg bw/day	General population [Consumers]	Systemic
	DNEL	Long term Inhalation	33 mg/m³	General population [Consumers]	Systemic
	DNEL	Long term Oral	1.67 mg/ kg bw/day	General population [Consumers]	Systemic
	DNEL	Long term Inhalation	33 mg/m³	General population	Local
	DNEL	Long term Inhalation	33 mg/m³	General population	Systemic
	DNEL	Long term Oral	36 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	275 mg/m³	Workers	Systemic
	DNEL	Long term Dermal	320 mg/kg bw/day	General population	Systemic
	DNEL	Short term Inhalation	550 mg/m³	Workers	Local
	DNEL	Long term Dermal	796 mg/kg bw/day	Workers	Systemic
n-butyl methacrylate	DNEL	Long term Dermal	3 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	5 mg/kg	Workers	Systemic

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 10/23

## **SECTION 8: Exposure controls/personal protection**

DNEL Dong term inhalation DNEL Long term inhalation DNEL Long term propulation DNEL Dong term Dermal DNEL Dong term DNEL DNE DNEL DNE DNE DNE DNE DNE	<u> </u>	<u> </u>	<u> </u>	I	<u> </u>	
Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   In				bw/day		
DNEL   DNEL   Long term   Inhalation   Inh		DNEL	Long term	66.5 mg/m <sup>3</sup>	General	Systemic
DNEL			Inhalation		population	-
DNEL		DNFI		366 4 mg/		Local
DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   DNEL   Long term   Inhalation   Inhal		5.122				20001
DNEL   Long term Dermal   Lon		DNE				Local
DNEL   Long term permal   DNEL   DNEL   Long term permal   DNEL   DNE		DINEL		409 mg/m <sup>3</sup>	workers	Local
DNEL						
DNEL Short term Dermal decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt with 1-methyl 10- (1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate  DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Drate Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Drate Inhalation DNEL Long term Drate Inhalation DNEL Long term Inha		DNEL	Long term	415.9 mg/	Workers	Systemic
DNEL Short term Dermal decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10- (1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate  DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dral DNEL DNEL DNE DNEL Long term Dral DNEL DNEL DNE DNE DNEL DNE DNEL DNE			Inhalation	m³		•
DNEL Cong term Dermal DNEL Coal population (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-pental DNEL Cong term Dormal DNEL Coal population (1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate  DNEL Cong term Dermal Cong term Dormal DNEL Cong term Dormal		DNFI		1 %	General	Local
DNEL Long term Dermal 1% Ceneral population workers Local DNEL Congulation Systemic population DNEL Congulation DNEL Congulat		2.122	Short term Berman	1 70		20001
DNEL Cong term Dermal DNEL Long term Dramal DNEL Dramal		DNE	1 t D 1	4.0/		1 1
DNEL   Long term Dermal   1 %   Workers   Local   DNEL   Long term Dermal   1 %   Workers   Local   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term   DNEL   Long		DNEL	Long term Dermai	1 %		Local
DNEL   Long term Dermal   1 % General population   DNEL   Long term Dermal population   DNEL   Long term Dermal population   DNEL   Long term						
DNEL   Long term Oral   D.31 mg/m   General population   Systemic population   Systemi		DNEL	Short term Dermal	1 %	Workers	Local
DNEL   Long term Oral   D.31 mg/m   General population   Systemic population   Systemi		DNEL	Long term Dermal	1 %	Workers	Local
(1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10- (1,2,2,6,6-pentamethyl-4-piperidinyl) decanedicate   DNEL   Long term   DnEL   DnEL   Long term   DnEL	decanedioic acid 1 10-bis					
ester, mixt. with 1-methyl 10- (1.2.2.6.5-pentamethyl-4-piperidinyl) decanedioate  DNEL Iong term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL			Long torm Oral			Cycloniic
1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate		all tyt <i>)</i>		ky bw/day	population	
decanedioate  DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dnemal DNEL Long term Dnemal DNEL Long term Dnemal DNEL Long term Dnemal DNEL Dnemal						
DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Long term DNEL Long term DNEL Long term DNEL Inhalation DNEL Long term DNEL Long term DNEL Inhalation DNEL Long term D	(1,2,2,6,6-pentamethyl-4-piperio	dinyl)				
Inhaiation   Long term Dermal   DNEL   Long term Dermal   Long term   Long term   Long term   DNEL   Long term Dermal   DNEL   Long term Dermal   DNEL   Long term   Long te	decanedioate					
Inhalation DNEL DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNFI	Long term	0.31 ma/m <sup>3</sup>	General	Systemic
DNEL Long term Dermal DNEL Long term Dermal Inhalation DNEL Cong term Dermal Inhalation DNEL DNEL Long term Dermal Inhalation DNEL DNEL Short term Inhalation DNEL Cong term Inhalation Inhalation DNEL Cong term Inhalation Inhalation DNEL Cong term Inhalation Inhal				3.5 ·g/		- , 5.5.7.115
DNEL long term inhalation DNEL long term Dermal DNEL long term Oral Oral Morkers Drotal Morkers		האורו		0 0 "		Cuetem-!-
DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhal		DNEL	Long term Dermal			Systemic
mesitylene  DNEL   Cong term Dermal   1.8 mg/kg bw/day   15 mg/kg bw/day   10 mg/m³						
mesitylene  DNEL   Cong term Dermal   1.8 mg/kg bw/day   15 mg/kg bw/day   10 mg/m³		DNEL	Long term	1.27 mg/m <sup>3</sup>	Workers	Systemic
DNEL   Long term Dermal   1.8 mg/kg bw/day   Systemic bw/day   DNEL   Long term Oral   15 mg/kg bw/day   29.4 mg/m³ lnhalation   DNEL   Long term   10.0 mg/m³ lnhalation   DNEL   Long term   1.0 mg/m³ lnhalation   DNEL   Long term   2.16 mg/m³   Workers   Systemic   Sy			Inhalation			
DNEL		DNEI		1.8 ma/ka	Workers	Systemic
mesitylene    DNEL   Cong term Oral   15 mg/kg bw/day   Ceneral population   Coal population   Ceneral population		DIVLE	Long term berman		VVOIROIS	Cystonio
DNEL Inhalation DNEL Cong term Dermal Inhalation DNEL Cong term Inhalation DNEL Short term Inhalation DNEL Cong term Dermal DNEL Cong term Dermal Inhalation DNEL Cong term Dermal DNEL Cong term DRED DNED DNED DNED DNED DNED DNED DNED		DAIE	1		0	0
DNEL Inhalation DNEL Cong term Dermal Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Dermal Cong term Dermal Inhalation DNEL Cong term Dermal Cong ter	mesityiene	DNEL	Long term Orai			Systemic
DNEL   Long term						
DNEL   Long term		DNEL	Short term	29.4 mg/m <sup>3</sup>	General	Local
DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL Long t			Inhalation			
Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNE		DNEI		20.4 mg/m <sup>3</sup>		Local
DNEL Short term Inhalation DNEL Cong term Dermal Inhalation DNEL Cong term Dermal Cong term Dermal Inhalation DNEL Cong term Dermal Inhalation DNEL Cong term Dermal Inhalation DNEL Cong term Dermal Cong term Inhalation DNEL Cong term Dermal Cong term Inhalation DNEL Cong term Dermal Cong term Der		DINCL		29.4 mg/m		Lucai
Inhalation DNEL Long term Inhalation DNEL Corp term Inhalation DNEL Co						
DNEL Long term Inhalation DNEL Short term Inhalation DNEL Cong term Dermal DNEL Cong term Dermal DNEL Cong term DN		DNEL		29.4 mg/m <sup>3</sup>		Systemic
Inhalation DNEL DNEL Long term Inhalation DNEL Long term Dormal DNEL Long term Dormal DNEL Long term Dormal Long term Dormal Long term Inhalation DNEL Long term Dormal DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dormal Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dormal DNEL Dorg term Dormal DORG DORG DORG DORG DORG DORG DORG DORG			Inhalation		population	
Inhalation DNEL DNEL Long term Inhalation DNEL Long term Dormal DNEL Long term Dormal DNEL Long term Dormal Long term Dormal Long term Inhalation DNEL Long term Dormal DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dormal Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dormal DNEL Dorg term Dormal DORG DORG DORG DORG DORG DORG DORG DORG		DNEL	Long term	29.4 mg/m <sup>3</sup>	General	Systemic
DNEL Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Cong term Dermal Inhalation DNEL Cong term Dermal Z.27 mg/ General Local				3		,
Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Short term 1.08 mg/m³ (General population) DNEL Long term 1.08 mg/m³ (General population) DNEL Short term 1.8 mg/m³ (General population) DNEL Short term 2.16 mg/m³ (General population) DNEL Short term 2.16 mg/m³ (General population) DNEL Short term 2.16 mg/m³ (General population) DNEL Long term Dermal 2.27 mg/ (General Local population)		DNEI		100 mg/m³		Local
DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal		DINEL		100 mg/m	Workers	Local
Inhalation DNEL Short term Inhalation DNEL Long term Dermal Long term Dermal DNEL Long term Dermal Long term Dermal Long term Dermal DNEL Long term Dermal DNEL Long term Dermal						
DNEL   Short term   100 mg/m³   Workers   Systemic		DNEL	Long term	100 mg/m <sup>3</sup>	Workers	Local
Inhalation DNEL Long term   100 mg/m³   Workers   Systemic   DNEL Long term Dermal   9512 mg/kg bw/day   16171 mg/kg bw/day   DNEL Short term   1.08 mg/m³   General   population   Systemic   DNEL Long term   1.08 mg/m³   General   population   Systemic   DNEL Short term   1.8 mg/m³   General   population   Systemic   DNEL Short term   1.8 mg/m³   General   population   DNEL   DNEL   Long term   DNEL			Inhalation			
Inhalation DNEL Long term   100 mg/m³   Workers   Systemic   DNEL Long term Dermal   9512 mg/kg bw/day   16171 mg/kg bw/day   DNEL Short term   1.08 mg/m³   General   population   Systemic   DNEL Long term   1.08 mg/m³   General   population   Systemic   DNEL Short term   1.8 mg/m³   General   population   Systemic   DNEL Short term   1.8 mg/m³   General   population   DNEL   DNEL   Long term   DNEL		DNEL	Short term	100 mg/m <sup>3</sup>	Workers	Systemic
DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Cong term Inhalation DNEL Cong term Inhalation DNEL Long ter						- ,
Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal  Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dermal		ראבו		100 mg/m3	Morkoro	Systemia
DNEL Long term Dermal PS12 mg/kg bw/day  DNEL Long term Dermal Population  DNEL Short term Inhalation DNEL Long term Dermal Population DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Population DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Population DNEL Long term Inhalation DNEL Long term Dermal Population DNEL Long term Inhalation DNEL Long term Dermal Population DNEL Long term Inhalation DNEL Long term Dermal Population DNEL Derma De		DINEL		100 mg/m²	VVOINCIS	Systemic
talc (non-asbestos form)  DNEL Short term Inhalation DNEL Long term Dermal						
talc (non-asbestos form)  DNEL Short term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL Lo		DNEL	Long term Dermal			Systemic
talc (non-asbestos form)  DNEL Short term Inhalation DNEL Long term Dermal  DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal					population	
talc (non-asbestos form)  DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation		DNEL	Long term Dermal		Workers	Systemic
talc (non-asbestos form)  DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Z.27 mg/ General Local		= :	J 3aii			'
Inhalation DNEL Long term	tale (non achastas form)	DVIEI	Short torm		Ceneral	Systemic
DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation	tale (non-aspesios form)	DINEL		1.00 mg/m²		Systemic
Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal						<u> </u>
DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Local		DNEL		1.08 mg/m³		Systemic
DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Local			Inhalation		population	
Inhalation DNEL Long term 1.8 mg/m³ General population DNEL Short term 2.16 mg/m³ Workers DNEL Long term 2.16 mg/m³ Workers Systemic  DNEL Long term 2.16 mg/m³ General Local  DNEL Long term 2.27 mg/ General Local		DNEI		1.8 ma/m³		Local
DNEL Long term   1.8 mg/m³   General   population   DNEL Short term   2.16 mg/m³   Workers   Systemic				,		
Inhalation DNEL Short term Inhalation DNEL Long term DNEL Long term Dermal		DVIEI		1 2 ma/m3		Local
DNEL Short term   2.16 mg/m³ Workers   Systemic		DINEL		1.0 mg/m²		LUCAI
Inhalation Long term Inhalation DNEL Long term Dermal 2.16 mg/m³ Workers Systemic  Systemic  Systemic  Long term Dermal 2.27 mg/ General  Local						
DNEL Long term 2.16 mg/m³ Workers Systemic Inhalation DNEL Long term Dermal 2.27 mg/ General Local		DNEL	Short term	2.16 mg/m³	Workers	Systemic
DNEL Long term 2.16 mg/m³ Workers Systemic Inhalation DNEL Long term Dermal 2.27 mg/ General Local			Inhalation			
Inhalation DNEL Long term Dermal 2.27 mg/ General Local		DNFI		2.16 ma/m <sup>3</sup>	Workers	Systemic
DNEL Long term Dermal 2.27 mg/ General Local				99/		- , 5.5.7.115
		חאורו		2 27 mal	Conoral	Local
cm² population		DINEL	Long term Dermal			LUGAI
				cm <sup>-</sup>	population	
	<u> </u>		<u> </u>	<u> </u>	<u> </u>	<u> </u>

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 11/23

## **SECTION 8: Exposure controls/personal protection**

		•			
	DNEL	Short term	3.6 mg/m <sup>3</sup>	Workers	Local
	DNEL	Inhalation Long term	3.6 mg/m <sup>3</sup>	Workers	Local
	DIVEL	Inhalation	3.0 mg/m	VVOIKEIS	Local
	DNEL	Long term Dermal	4.54 mg/ cm <sup>2</sup>	Workers	Local
	DNEL	Long term Dermal	21.6 mg/ kg bw/day	General population	Systemic
	DNEL	Long term Dermal	43.2 mg/ kg bw/day	Workers	Systemic
	DNEL	Short term Oral	160 mg/kg bw/day	General population	Systemic
	DNEL	Long term Oral	160 mg/kg bw/day	General population	Systemic
Oleic acid, compound	DNEL	Long term Oral	5 μg/kg bw/ day		Systemic
	DNEL	Long term Dermal	5 μg/kg bw/ day		Systemic
	DNEL	Long term Dermal	14 µg/kg bw/day	Workers	Systemic
	DNEL	Long term	17.4 μg/m³	General	Systemic
	DNEL	Inhalation Long term	98.4 µg/m³	population Workers	Systemic
	DIVEL	Inhalation	90.4 μg/III	VVOIKEIS	Systemic
dioctyltin dilaurate	DNEL	Long term Oral	0.0005 mg/		Systemic
	DNEL	Long term	kg bw/day 0.0009 mg/	population General	Systemic
	DIVEE	Inhalation	m <sup>3</sup>	population	Oysternio
	DNEL	Long term Inhalation	0.0035 mg/ m <sup>3</sup>	Workers	Systemic
Toluene	DNEL	Long term Inhalation	384 mg/m³	Workers	Systemic
	DNEL	Long term Oral	8.13 mg/ kg bw/day	General population	Systemic
	DNEL	Long term	56.5 mg/m <sup>3</sup>		Local
	DNEL	Inhalation Long term	56.5 mg/m³		Systemic
	DNEL	Inhalation Long term	192 mg/m³	population Workers	Local
	DNEL	Inhalation Long term Inhalation	192 mg/m³	Workers	Systemic
	DNEL	Long term Dermal	226 mg/kg bw/day	General population	Systemic
	DNEL	Short term Inhalation	226 mg/m <sup>3</sup>	General population	Local
	DNEL	Short term Inhalation	226 mg/m <sup>3</sup>	General population	Systemic
	DNEL	Long term Dermal	384 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	384 mg/m³	Workers	Local
	DNEL	Short term Inhalation	384 mg/m³	Workers	Systemic
maleic anhydride	DNEL	Long term Inhalation	0.081 mg/ m <sup>3</sup>	Workers	Local
	DNEL	Long term Inhalation	0.081 mg/ m³	Workers	Systemic
	DNEL	Short term Inhalation	0.2 mg/m <sup>3</sup>	Workers	Local
	DNEL	Short term Inhalation	0.2 mg/m <sup>3</sup>	Workers	Systemic
	DNEL	Long term Inhalation	0.05 mg/m <sup>3</sup>	General population	Systemic
	[				<u> </u>

Date of issue/Date of revision: 28.03.2023Date of previous issue: No previous validationVersion: 1

## **SECTION 8: Exposure controls/personal protection**

ONEL	Long term Oral	0.06 mg/	General	Systemic
		kg bw/day	population	
ONEL	Long term	0.08 mg/m <sup>3</sup>	General	Local
	Inhalation		population	
DNEL	Short term Oral	0.1 mg/kg	General	Systemic
		bw/day	population	
ONEL	Short term Dermal	0.1 mg/kg	General	Systemic
		bw/day	population	
DNEL	Long term Dermal	0.1 mg/kg	General	Systemic
		bw/day	population	
ONEL	Short term Dermal	0.2 mg/kg	Workers	Systemic
		bw/day		
ONEL	Long term Dermal	0.2 mg/kg	Workers	Systemic
		bw/day		

#### **PNECs**

Product/ingredient name	<b>Compartment Detail</b>	Value	Method Detail
xylene	Fresh water	0.327 mg/l	-
	Marine	0.327 mg/l	-
	Sewage Treatment Plant	6.58 mg/l	-
	Fresh water sediment	12.46 mg/kg dwt	-
	Marine water sediment	12.46 mg/kg dwt	-
	Soil	2.31 mg/kg dwt	-
n-butyl acetate	Fresh water	0.18 mg/l	-
•	Marine	0.018 mg/l	-
	Sewage Treatment Plant	35.6 mg/l	-
	Fresh water sediment	0.981 mg/kg dwt	_
	Marine water sediment	0.0981 mg/kg dwt	_
	Soil	0.0903 mg/kg dwt	_
ethylbenzene	Fresh water	0.1 mg/l	_
,	Marine	0.01 mg/l	-
	Sewage Treatment Plant	9.6 mg/Ĭ	-
	Fresh water sediment	13.7 mg/kg dwt	_
	Soil	2.68 mg/kg dwt	_
	Secondary Poisoning	20 mg/kg	_
2-methoxy-1-methylethyl acetate	Fresh water	0.635 mg/l	-
, , ,	Marine	0.0635 mg/l	-
	Sewage Treatment Plant	100 mg/l	-
	Fresh water sediment	3.29 mg/kg dwt	-
	Marine water sediment	0.329 mg/kg dwt	-
	Soil	0.29 mg/kg dwt	-
Toluene	Fresh water	0.68 mg/l	-
	Marine	0.68 mg/l	-
	Sewage Treatment Plant	13.61 mg/l	-
	Fresh water sediment	16.39 mg/kg dwt	-
	Marine water sediment	16.39 mg/kg dwt	-
	Soil	2.89 mg/kg dwt	-

#### 8.2 Exposure controls

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

**Individual protection measures** 

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 13/23

## **SECTION 8: Exposure controls/personal protection**

#### **Hygiene measures**

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

#### **Eye/face protection**

: Safety eyewear complying to ISO 16321-1:2022 should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

#### **Skin protection**

#### **Hand protection**

There is no one glove material or combination of materials that will give unlimited resistance to any individual or combination of chemicals.

The breakthrough time must be greater than the end use time of the product.

The instructions and information provided by the glove manufacturer on use, storage, maintenance and replacement must be followed.

Gloves should be replaced regularly and if there is any sign of damage to the glove material.

Always ensure that gloves are free from defects and that they are stored and used correctly.

The performance or effectiveness of the glove may be reduced by physical/chemical damage and poor maintenance.

Barrier creams may help to protect the exposed areas of the skin but should not be applied once exposure has occurred.

#### **Gloves**

Wear suitable gloves tested to ISO 374-1:2016.

May be used, gloves(breakthrough time) 4 - 8 hours: butyl rubber (> 0.4 mm), neoprene (> 0.35 mm), PVC (> 0.5 mm)

Not recommended, gloves(breakthrough time) < 1 hour: Viton® (> 0.7 mm)

Recommended, gloves(breakthrough time) > 8 hours: Teflon (> 0.35 mm), 4H/Silver Shield® (> 0.07 mm), polyvinyl alcohol (PVA) (> 0.3 mm), nitrile rubber (> 0.4 mm)

For right choice of glove materials, with focus on chemical resistance and time of penetration, seek advice by the supplier of chemical resistant gloves.

The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.

#### **Body protection**

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves.

#### Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

### Respiratory protection

: If workers are exposed to concentrations above the exposure limit, they must use a respirator according to EN 140. Use respiratory mask with charcoal and dust filter when spraying this product, according to EN 14387 (as filter combination A2-P2). In confined spaces, use compressed-air or fresh-air respiratory equipment. When use of roller or brush, consider use of charcoalfilter.

## **Environmental exposure** controls

: Do not allow to enter drains or watercourses.

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 14/23

## **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

**Appearance** 

Physical state : Liquid.

Colour : Brown., Black, Blue., Brown., Clear., Green., Grey, MCI Base 1, MCI Base 2,

MCI Base 3, MCI Base 5, MCI Base 6, Off-white., Orange, Purple., Red, Metallic,

Violet., White., Yellow.

Odour : Characteristic. **Odour threshold** : Not applicable. Melting point/freezing point : Not applicable.

Initial boiling point and

boiling range

Lowest known value: 126°C (258.8°F) (n-butyl acetate). Weighted average:

140.57°C (285°F)

**Flammability** Upper/lower flammability or

explosive limits

: 0.8 - 9.8%

: Not applicable.

Flash point : Closed cup: 32°C (89.6°F)

Lowest known value: 280 to 470°C (536 to 878°F) (hydrocarbons, C9, **Auto-ignition temperature** 

aromatics).

**Decomposition temperature** : Not available. pН Not applicable.

**Viscosity** Kinematic (40°C): >20.5 mm<sup>2</sup>/s

Solubility(ies)

Media	Result
cold water	Not soluble
hot water	Not soluble

Partition coefficient: n-octanol/ : Not available.

water

Vapour pressure : Highest known value: 1.5 kPa (11.3 mm Hg) (at 20°C) (n-butyl acetate).

Weighted average: 0.95 kPa (7.13 mm Hg) (at 20°C)

**Evaporation rate** Highest known value: 1 (n-butyl acetate) Weighted average: 0.78compared with

butyl acetate

**Density** : 1.205 to 1.452 g/cm<sup>3</sup>

Highest known value: 4 (Air = 1) (n-butyl acetate). Weighted average: 3.78 Vapour density

(Air = 1)

**Explosive properties** Not available. **Oxidising properties** : Not available.

**Particle characteristics** 

Median particle size : Not applicable.

#### 9.2 Other information

No additional information.

## SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : Stable under recommended storage and handling conditions (see Section 7).

10.3 Possibility of : Under normal conditions of storage and use, hazardous reactions will not occur.

hazardous reactions

10.4 Conditions to avoid : When exposed to high temperatures may produce hazardous decomposition

products.

10.5 Incompatible materials Keep away from the following materials to prevent strong exothermic reactions: oxidising agents, strong alkalis, strong acids.

Date of issue/Date of revision : 28.03.2023 : 1 15/23 Date of previous issue : No previous validation Version

## **SECTION 10: Stability and reactivity**

10.6 Hazardous decomposition products

Decomposition products may include the following materials: carbon monoxide, carbon dioxide, smoke, oxides of nitrogen.

## **SECTION 11: Toxicological information**

#### 11.1 Information on toxicological effects

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains n-butyl methacrylate, 2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester, polymer with butyl 2-propenoate, comps. with polyethylene glycol hydrogen maleate C9-11-alkyl ethers, decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate. May produce an allergic reaction.

#### **Acute toxicity**

Product/ingredient name	Result	Species	Dose	Exposure
xylene	LC50 Inhalation Vapour	Rat	20 mg/l	4 hours
	LD50 Oral	Rat	4300 mg/kg	-
	TDLo Dermal	Rabbit	4300 mg/kg	-
n-butyl acetate	LC50 Inhalation Vapour	Rat	>21.1 mg/l	4 hours
	LD50 Dermal	Rabbit	>17600 mg/kg	-
	LD50 Oral	Rat	13100 mg/kg	-
ethylbenzene	LC50 Inhalation Vapour	Rat - Male	17.8 mg/l	4 hours
•	LD50 Dermal	Rabbit	>5000 mg/kg	-
	LD50 Oral	Rat	3500 mg/kg	-
2-methoxy-1-methylethyl	LD50 Dermal	Rabbit	>5 g/kg	-
acetate				
	LD50 Oral	Rat	8532 mg/kg	-
n-butyl methacrylate	LD50 Oral	Rat	16 g/kg	-
mesitylene	LC50 Inhalation Vapour	Rat	24000 mg/m <sup>3</sup>	4 hours
•	LD50 Oral	Rat	5000 mg/kg	-
toluene	LC50 Inhalation Vapour	Rat	49 g/m³	4 hours
	LD50 Oral	Rat	636 mg/kg	-
maleic anhydride	LD50 Oral	Rat	400 mg/kg	-

#### **Acute toxicity estimates**

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
Hardtop XP Comp A (MM-WCSE)	N/A	9487.6	N/A	125.4	N/A
xylene	4300	1100	N/A	20	N/A
n-butyl acetate	13100	N/A	N/A	N/A	N/A
ethylbenzene	3500	N/A	N/A	17.8	N/A
2-methoxy-1-methylethyl acetate	8532	N/A	N/A	N/A	N/A
n-butyl methacrylate	16000	N/A	N/A	N/A	N/A
mesitylene	5000	N/A	N/A	24	N/A
toluene	N/A	N/A	N/A	49	N/A
maleic anhydride	400	N/A	N/A	N/A	N/A

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 16/23

## **SECTION 11: Toxicological information**

#### Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
xylene	Eyes - Mild irritant	Rabbit	-	87 milligrams	-
,	Skin - Mild irritant	Rat	-	8 hours 60 microliters	-
titanium dioxide	Skin - Mild irritant	Human	-	72 hours	-
n-butyl methacrylate	Eyes - Mild irritant	Mammal - species unspecified	-	-	-
	Skin - Mild irritant	Rabbit	-	500 microliters	-
mesitylene	Eyes - Mild irritant	Rabbit	-	24 hours 500 milligrams	-
	Skin - Moderate irritant	Rabbit	-	24 hours 20 milligrams	-
toluene	Skin - Moderate irritant	Rabbit	-	24 hours 20 milligrams	-
maleic anhydride	Eyes - Severe irritant	Rabbit	-	1 Percent	-

#### **Sensitisation**

Product/ingredient name	Route of exposure	Species	Result
n-butyl methacrylate	skin	Mammal - species unspecified	Sensitising
2-Propenoic acid, 2-methyl-, 2-(dimethylamino)ethyl ester, polymer with butyl 2-propenoate, comps. with polyethylene glycol hydrogen maleate C9-11-alkyl ethers	skin	Mammal - species unspecified	Sensitising
maleic anhydride	skin	Mammal - species unspecified	Sensitising

#### **Mutagenicity**

No known significant effects or critical hazards.

#### **Carcinogenicity**

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

No known significant effects or critical hazards.

### **Reproductive toxicity**

Developmental effects : No known significant effects or critical hazards.

Fertility effects : No known significant effects or critical hazards.

#### **Teratogenicity**

No known significant effects or critical hazards.

#### Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
xylene	Category 3	-	Respiratory tract irritation
n-butyl acetate	Category 3	-	Narcotic effects
hydrocarbons, C9, aromatics	Category 3	-	Respiratory tract irritation
	Category 3		Narcotic effects
2-methoxy-1-methylethyl acetate	Category 3	-	Narcotic effects
n-butyl methacrylate	Category 3	-	Respiratory tract irritation
mesitylene	Category 3	-	Respiratory tract irritation
toluene	Category 3	-	Narcotic effects

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 17/23

## **SECTION 11: Toxicological information**

#### Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
dioctyltin dilaurate	Category 2 Category 2 Category 1 Category 2 Category 1	- - - - inhalation	hearing organs - immune system - respiratory system

#### **Aspiration hazard**

Product/ingredient name	Result
xylene ethylbenzene hydrocarbons, C9, aromatics mesitylene toluene	ASPIRATION HAZARD - Category 1

#### Potential acute health effects

**Eye contact** : Causes serious eye irritation.

Inhalation : No known significant effects or critical hazards.

**Skin contact**: Causes skin irritation. May cause an allergic skin reaction.

Ingestion : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : Adverse symptoms may include the following:

pain or irritation watering redness

Inhalation : No specific data.

**Skin contact**: Adverse symptoms may include the following:

irritation redness

**Ingestion** : No specific data.

General: Once sensitized, a severe allergic reaction may occur when subsequently exposed

to very low levels.

Other information : None identified.

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

There are no data available on the mixture itself.

Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

Product/ingredient name	Result	Species	Exposure
xylene	Acute LC50 8500 μg/l Marine water	Crustaceans - Daggerblade grass shrimp - Palaemonetes pugio	48 hours
	Acute LC50 13400 μg/l Fresh water	Fish - Fathead minnow - Pimephales promelas	96 hours
ethylbenzene	Acute EC50 7700 μg/l Marine water	Algae - Diatom - Skeletonema costatum	96 hours
	Acute EC50 2.93 mg/l	Daphnia	48 hours
	Acute LC50 4.2 mg/l	Fish	96 hours
titanium dioxide	Acute LC50 3 mg/l Fresh water	Crustaceans - Water flea - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 6.5 mg/l Fresh water	Daphnia - Water flea - Daphnia pulex - Neonate	48 hours
	Acute LC50 >1000000 μg/l Marine	Fish - Mummichog - Fundulus	96 hours

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 18/23

## **SECTION 12: Ecological information**

	water	heteroclitus	
hydrocarbons, C9, aromatics		Daphnia	48 hours
	Acute IC50 <10 mg/l	Algae	72 hours
	Acute LC50 <10 mg/l	Fish	96 hours
n-butyl methacrylate	Chronic NOEC 2.6 mg/l Fresh water	Daphnia - Water flea - Daphnia magna - Neonate	21 days
decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate	Acute EC50 1.68 mg/l	Algae	96 hours
' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	Acute LC50 0.9 mg/l	Fish	96 hours
	Chronic NOEC 1 mg/l	Daphnia	21 days
mesitylene	Acute LC50 12520 to 15050 µg/l Fresh	Fish - Goldfish - Carassius	96 hours
	water	auratus	
maleic anhydride	Acute LC50 230 ppm Fresh water	Fish - Western mosquitofish - Gambusia affinis - Adult	96 hours

**Conclusion/Summary** 

: This material is harmful to aquatic life with long lasting effects.

### 12.2 Persistence and degradability

**Conclusion/Summary**: Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
xylene ethylbenzene hydrocarbons, C9, aromatics mesitylene	- - -	-	Readily Readily Not readily Not readily

#### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
xylene	3.12	8.1 to 25.9	low
n-butyl acetate	2.3	-	low
ethylbenzene	3.6	-	low
hydrocarbons, C9, aromatics	-	10 to 2500	high
2-methoxy-1-methylethyl acetate	1.2	-	low
n-butyl methacrylate	2.99	-	low
mesitylene	3.42	161	low
dioctyltin dilaurate	-	<100	low
toluene	2.73	90	low
maleic anhydride	-2.78	-	low

## 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility : Not available.

## 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**12.6 Other adverse effects**: No known significant effects or critical hazards.

Date of issue/Date of revision: 28.03.2023Date of previous issue: No previous validationVersion: 119/23

## **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

#### **Hazardous waste**

: Yes.

#### Waste catalogue

Waste code	Waste designation
08 01 11*	Waste paint and varnish containing organic solvents or other dangerous substances

#### **Packaging**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Type of packaging	Waste catalogue	
CEPE Guidelines	15 01 10*	packaging containing residues of or contaminated by hazardous substances

#### **Special precautions**

This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	IATA
14.1 UN number	UN1263	UN1263	UN1263	UN1263
14.2 UN proper shipping name	Paint	Paint	Paint	Paint
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	III	III	III	III
14.5 Environmental hazards	No.	Yes.	No.	No.

## <u>Additional information</u>

ADR/RID

: Hazard identification number 30

**Special provisions** 640E

Tunnel code (D/E)

ADR/RID: Viscous substance. Not restricted, ref. chapter 2.2.3.1.5 (applicable to receptacles < 450 litre capacity).

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 20/23

## **SECTION 14: Transport information**

**ADN** 

: The product is only regulated as an environmentally hazardous substance when transported in tank vessels.

**IMDG** 

: Emergency schedules F-E, S-E

IMDG: Viscous substance. Transport in accordance with paragraph 2.3.2.5

(applicable to receptacles < 450 litre capacity).

14.6 Special precautions for

user

: **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

Not available.

## **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture UK (GB)/REACH

### Annex XIV - List of substances subject to authorisation

#### **Annex XIV**

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

#### Ozone depleting substances

Not listed.

### **Prior Informed Consent (PIC)**

Not listed.

### **Persistent Organic Pollutants**

Not listed.

Annex XVII - Restrictions : Not applicable.

on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

#### **Seveso Directive**

This product is controlled under the Seveso Directive.

### Danger criteria

#### **Category**

P5c

#### **EU regulations**

Industrial emissions

: Not listed

(integrated pollution prevention and control) -

Air

Industrial emissions

: Not listed

(integrated pollution prevention and control) -

Water

#### **International regulations**

Chemical Weapon Convention List Schedules I, II & III Chemicals

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 21/23

## **SECTION 15: Regulatory information**

Not listed.

#### **Montreal Protocol**

Not listed.

#### **Stockholm Convention on Persistent Organic Pollutants**

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

## **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

GB CLP = UK CLP (EC No 1272/2008) on the Classification, Labelling and

Packaging of Substances and Mixtures as amended by (EU Exit) Regulations 2019

No. 720 and amendments

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = GB CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

#### Procedure used to derive the classification

Classification	Justification	
Flam. Liq. 3, H226	On basis of test data	
Skin Irrit. 2, H315	Calculation method	
Eye Irrit. 2, H319	Calculation method	
Skin Sens. 1, H317	Calculation method	
Aquatic Chronic 3, H412	Calculation method	

## Full text of abbreviated H statements

H225	Highly flammable liquid and vapour.	•
H226	Flammable liquid and vapour.	
H302	Harmful if swallowed.	
H304	May be fatal if swallowed and enters airways.	
H312	Harmful in contact with skin.	
H314	Causes severe skin burns and eye damage.	
H315	Causes skin irritation.	
H317	May cause an allergic skin reaction.	
H318	Causes serious eye damage.	
H319	Causes serious eye irritation.	
H332	Harmful if inhaled.	
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.	
H335	May cause respiratory irritation.	
H336	May cause drowsiness or dizziness.	
H351	Suspected of causing cancer.	
H360D	May damage the unborn child.	
H361d	Suspected of damaging the unborn child.	
H361f	Suspected of damaging fertility.	
H372	Causes damage to organs through prolonged or repeated exposure.	
H373	May cause damage to organs through prolonged or repeated exposure.	

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 22/23

### **SECTION 16: Other information**

H400 Very toxic to aquatic life.
 H410 Very toxic to aquatic life with long lasting effects.
 H411 Toxic to aquatic life with long lasting effects.

H412 Harmful to aquatic life with long lasting effects.

EUH066 Repeated exposure may cause skin dryness or cracking.

EUH071 Corrosive to the respiratory tract.

#### Full text of classifications

Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
Aquatic Chronic 2
Aquatic Chronic 3
Asp. Tox. 1
Acute ToxICITY - Category 4
SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
ASPIRATION HAZARD - Category 1
CARCINOGENICITY - Category 2

Eye Dam. 1 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2

Flam. Liq. 2
Flam. Liq. 2
Flam. Liq. 3
FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3
Repr. 1B
Repr. 2
Repr. 2
Resp. Sens. 1
Skin Corr. 1B
Skin Irrit. 2
FLAMMABLE LIQUIDS - Category 2
REPRODUCTIVE TOXICITY - Category 1B
REPRODUCTIVE TOXICITY - Category 2
RESPIRATORY SENSITISATION - Category 1
SKIN CORROSION/IRRITATION - Category 1B

Skin Sens. 1 SKIN SENSITISATION - Category 1
Skin Sens. 1A SKIN SENSITISATION - Category 1A

STOT RE 1 SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1
STOT RE 2 SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2
STOT SE 3 SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3

Date of printing : 28.03.2023 Date of issue/ Date of : 28.03.2023

revision

Date of previous issue : No previous validation

Version : 1

#### Notice to reader

The information in this document is given to the best of Jotun's knowledge, based on laboratory testing and practical experience. Jotun's products are considered as semi-finished goods and as such, products are often used under conditions beyond Jotun's control. Jotun cannot guarantee anything but the quality of the product itself. Minor product variations may be implemented in order to comply with local requirements. Jotun reserves the right to change the given data without further notice.

Date of issue/Date of revision : 28.03.2023 Date of previous issue : No previous validation Version : 1 23/23